Project Grant 2451001
Award Date
4/15/25
Completion Date
9/30/26
Dollars Obligated
$305K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Olivette, MO 63132, USA
Similar Awards
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Program Project Grant of $275,000 awarded to Beken Bio, Inc. aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancer by assaying relevant biomarkers on circulating extracellular vesicles in patient plasma. The project objectives are to identify key proteins in extracellular vesicles from various ovarian cancer subtypes and employ machine learning to...
This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program (CFDA 47.084) provides $275,000 to Dcan Biosciences LLC to develop an advanced microfluidic system for cancer diagnosis and monitoring. The system aims to isolate and assess circulating tumor cells (CTCs) and CTC clusters (CTCCs) from patient blood samples to enable highly sensitive and accurate liquid biopsies. Key objectives include designing a hybrid microfluidic device for...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
The National Cancer Institute (NCI) awarded a $927,997 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to Lagrange Scientific LLC in Pewee Valley, KY. The goal of this 3-year Phase II SBIR project is to further develop a prognostic assay to accurately predict early metastasis in clear cell renal cell carcinoma (CCRCC) patients. The project aims to validate a 12-metabolite biomarker panel that was shown in pilot studies to identify with 100% specificity and...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
The federal Project Grant award of $821,797 from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development and clinical validation of an innovative bladder cancer diagnostic assay called BCDX. BCDX employs advanced nanotechnology to detect twelve different biomarkers from a urine sample, including proteins, miRNAs, mRNAs, and lncRNAs. Feasibility studies have demonstrated high sensitivity and predictive values for BCDX in...
This $449,996 federal Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) aims to develop a highly sensitive, low-cost sensor platform to detect circulating tumor DNA (ctDNA) - a key biomarker for early cancer diagnosis, particularly in non-small cell lung cancer. Researchers at the University of Minnesota, in collaboration with the University of Cambridge, are combining microwave photonics and polymer-based micro-ring resonator technology to create...
The National Science Foundation awarded $256,000 to Optave Diagnostics LLC through the Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a prototype endoscopic probe for molecular imaging and diagnosis of cancerous prostate pathologies. The 12-month project grant will support the creation of a medical device using photoacoustic imaging and acoustic lens technology to aid in the detection and diagnosis of prostate cancer. The proposed endoscopic probe offers an alternative...
This $274,990 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) supports the development of a novel optical method for detecting microscopic tumors to enable more rapid and accurate point-of-care cancer diagnoses. The project aims to integrate plasmonic nanobubble sensors into a medical device platform and endoscope to perform minimally invasive, non-invasive cancer diagnostic procedures. The key product being...
The National Science Foundation (NSF) has awarded a $1,000,000 Cooperative Agreement under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to Aidar Health, Inc.'s Rapid Advantage Division. The purpose of this 2-year award is to develop a comprehensive remote health management system for patients with chronic kidney disease. Key deliverables include a medical device, digital tools with advanced analytics capabilities, and a novel patient engagement feature using...